nach oben

Erschienen in:

01.06.2019 | Case report

Sorafenib

Fatigue: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study of 132 patients performed between January 2010 and December 2014, a patient [age and sex not stated] was described, who experienced fatigue during treatment with sorafenib for hepatocellular carcinoma (HCC). The patient, who had HCC started receiving combination treatment with sorafenib 400mg twice daily [route not stated] and transarterial chemoembolisation (TACE). However, the patient experienced grade II fatigue [duration of treatment to reaction onset and outcome not stated]. The patient continued to receive sorafenib. …

Wang E, et al. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma. BMC Cancer 19: 409, No. 1, 30 Apr 2019. Available from: URL: http://doi.org/10.1186/s12885-019-5570-z - China

Titel: Sorafenib
Fatigue: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63870-x

Springer Medizin

Sorafenib

Fatigue: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Lamivudine

Sorafenib

Semaglutide: no increased risk of cardiovascular events

Metformin

Lamotrigine/oxazepam/quetiapine overdose

Hydrogen peroxide

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Lamivudine

Sorafenib

Semaglutide: no increased risk of cardiovascular events

Metformin

Lamotrigine/oxazepam/quetiapine overdose

Hydrogen peroxide